Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia C ...

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.346
https://www.valueinhealthjournal.com/article/S1098-3015(13)02251-1/fulltext
Title : Cost-Consequence Analysis of a Treatment Strategy Including Ponatinib Compared to a Treatment Strategy Including Only the 2nd Generation Tyrosine Kinase Inhibitors (2g TKIs), Dasatinib or Nilotinib, in Resistant Patients with Philadelphia C ...
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02251-1&doi=10.1016/j.jval.2013.08.346
First page : A382
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 327
Categories :
Tags :
Regions :
ViH Article Tags :